Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Publications
12.10.2022
ISPOR 2022: Comparing and contrasting Early Access...

We've researched early access programmes across the UK and EU4 to establish the eligibility criteria...

Read more
Articles
24.08.2022
How do you win the race to market? Our top conside...

Introduction Early Access Programs, also known as special access programs, give patients access to m...

Read more
Articles
24.08.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
Articles
24.08.2022
What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Read more
Articles
24.08.2022
Regulators are giving early access to medicines, b...

Introduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...

Read more
Articles
07.12.2021
What are the 5 Pricing & Market Access trends...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
Articles
04.12.2020
What are the 5 Pricing and Market Access trends th...

Our experts predict the 5 trends they think will dominate the European pricing and market access lan...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch